MedChemComm

Supporting Info

Cite this: DOI: 10.1039/x0xx00000x

Synthesis and evaluation of linear CuAAColigomerized antifreeze neo-glycopeptides

S. van der Wal^a, C.J. Capicciotti^b, S. Rontogianni^a, R.N. Ben^b, R.M.J. Liskamp*^a

Received 00th January 2012, Accepted 00th January 2012

DOI: 10.1039/x0xx00000x

www.rsc.org/

Materials and methods

General: All reactions were carried out at ambient temperatures unless stated otherwise. Solvents used in these synthesis procedures were supplied by BioSolve BV, (Valkenswaard, The Netherlands) and stored over molecular sieves (CH2Cl2 and THF on 4Å and MeCN on 3Å). Routine analysis of reaction progression and product identity was checked by thin layer chromatography (TLC) on Merck precoated silicagel 60F₂₅₄ glass plates. Spots were visualized by UV light and stained by ninhydrin or sulphuric acid charring for (protected) amine- and carbohydrate moieties respectively. Column chromatography was performed using Silicycle Siliflash P60 (40-63 µm) silicagel obtained from Screening Devices (Amersfoort, The Netherlands)

¹H NMR spectra, ¹³C and Attached proton test (APT) spectra were recorded on a Varian Gemini 300 spectrometer at 300 MHz and 75 MHz respectively. High pressure liquid chromatography was performed analytically on a Shimadzu automated HPLC system with a dual wavelength detector at 220 and 254 nm operating at a flowrate of 1 ml/min. An Alltech Alltima C8 column (100 Å, 5 µm, 250 x 4.6 mm) column was used together with acetonitrile TFA buffers for elution (buffer A: 5:95 MeCN:H₂O v/v + 0.1% TFA and buffer B: 95:5 MeCN:H₂O v/v + 0.1% TFA) in a 20- or 48 minute gradient. Preparative HPLC was performed on an Applied Biosystems system using identical buffers and an Alltech Alltima C8 column (100 Å, 10 µm, 250 x 22 mm) and a gradient of 100 minutes. Electron spray mass spectrometry was performed on a Shimadzu LCMS-QP8000 single quadrupole spectrometer operating in positive mode. MALDI-TOF analysis was performed on a Kratos Axima CFR spectrometer using α -cyano-4-hydroxycinnamic acid as matrix.

(S)-2-azido-5-((tert-butoxycarbonyl)amino)pentanoic acid (2)

To a solution of H-Orn(Boc)-OH (4.73 g, 20 mmol) in MeOH (100 ml), copper sulfate solution (42 mg, 0.2 mmol) in water (100 ml) was added, followed by K₂CO₃ (6.14 g, 44 mmol). Subsequently solid imidazole-1-sulfonyl-azide hydrochloride¹ (5.13 g, 24 mmol) was added and the reaction mixture was stirred for 4 hours. The reaction mixture was concentrated to about 100 ml, acidified with 1 M KHSO₄ and extracted with EtOAc. The organic layer was washed with saturated sodium chloride and dried with Na₂SO₄. After filtration and concentration in vacuo, the residual oil was dissolved in Et₂O and dicyclohexylamine (4 ml, 20 mmol) was added dropwise while stirring. After cooling at -20 °C overnight the white precipitate was collected by filtration and dried in vacuo to obtain the dicyclohexylamine salt of (S)-2-azido-5-((tertbutoxycarbonyl)amino) pentanoic acid (8.28 g, 18.8 mmol, 94%) as a fine white powder.

The free acid for subsequent reactions and analysis was obtained by suspending the salt in EtOAc in an extraction funnel and washing with 1 M KHSO₄. After drying the organic layer with saturated NaCl and Na₂SO₄ the free acid was obtained as an oil in near quantitative

yield. ¹H NMR (CDCl₃): $\delta = 10.40$ (bs, 1H, COOH), 6.46 + 4.72 (two bs. 1H, NH), 3.93 (bs, 1H, α-CH), 3.15 (bs, 2H, δ-CH₂), 1.89-1.77 (m, 2H, β-CH₂), 1.63 (m, 2H, γ-CH₂), 1.44 (s, 9H, Boc-CH₃)

¹H NMR (CD₃OD): δ = 3.98 (m, 1H, α-CH), 3.07 (t, *J*= 6.6 Hz, 2H, δ-CH₂), 1.91-1.68 (m, 2H, β-CH₂), 1.59 (m, 2H, γ-CH₂), 1.43 (s, 9H, Boc-CH₃)

¹³C NMR (CD₃OD) δ = 172.4, 157.1, 78.5, 61.5, 39.2, 28.3, 27.4, 259

((N-tert-butoxycarbonyl)glycyl)-propargylamine (3a)

Propargylamine hydrochloride (4.25 g, 40 mmol) and Boc-Gly-OH (6.90 g, 40 mmol) were dissolved in CH₂Cl₂ (250 ml). The stirred mixture was cooled on ice, and diisopropylethylamine (DiPEA, 21 ml, 120 mmol) was added, followed by BOP (17.60 g, 40 mmol). After stirring for 2h at room temperature, the mixture was concentrated, redissolved in EtOAc and subsequently washed with 1 M KHSO₄, 5% NaHCO₃ and saturated NaCl. After drying with Na₂SO₄, the product was crystallized from CH₂Cl₂/ hexanes to yield colourless crystals of ((N-tert-butoxycarbonyl)glycyl)propargylamine (6.6 g, 31 mmol, 79% overall yield). ¹H NMR (CDCl₃): $\delta = 6.46$ (bs, 1H, amide-NH), 5.16 (bs, 1H, Boc-

NH), 4.06 (dd, J₁=2.5 Hz, J₂=5.3 Hz, 2H, CH₂-propargyl), 3.81 (d, J=5.8 Hz, 2H, glycine-CH₂), 2.23 (t, J=2.5 Hz, 1H, alkyne-H), 1.45 (s, 9H, Boc-CH₃) ¹³C NMR (CDCl₃): $\delta = 169.3$, 156.1, 80.4, 79.2, 71.6, 44.3, 29.0,

28.3

Triisopropylsilyl-((N-tert-butoxycarbonyl)glycyl)propargylamine (3b)

3-Triisopropylsilyl-propargylamine² (5.0 g, 23 mmol), Boc-Gly-OH

This journal is © The Royal Society of Chemistry 2013

RSCPublishing

(3.83 g, 21.9 mmol) and DiPEA (11.6 ml, 21.9 mmol) were dissolved in CH₂Cl₂ (200 ml) and cooled on ice. While stirring, BOP (9.68 g, 21.9 mmol) was added. After 3 hours at room temperature the reaction mixture was concentrated *in vacuo* and redissolved in EtOAc. This was washed with 1 M KHSO₄, 5% NaHCO₃ and saturated NaCl. After drying with Na₂SO₄ and concentration *in vacuo*, Triisopropylsilyl-((N-tert-butoxycarbonyl)glycyl)-propargylamine was obtained as a yellowish oil that solidified upon standing (8.61 gram, 23 mmol, 99%) ¹H NMR (CDCl₃): $\delta = 6.19$ (bs, 1H, amide-NH), 5.08 (m, 1H, Boc-NH), 4.11 (m, 2H, CH₂-propargyl), 3.80 (d, *J*=5.9 Hz, 2H, glycine-CH₂), 1.46 (s, 9H Boc-CH₃), 1.06 (s, 21H, TIPS)

¹³C NMR (CDCl₃): $\delta = 169.0$, 156.2, 102.4, 84.8, 80.3, 44.3, 30.2, 28.3, 18.5, 11.1

(S)-2-azido-5-((tert-butoxycarbonyl)amino)pentanoyl-glycylpropargylamine (4a)

The Boc-group in **3a** (2.0 g, 9.4 mmol) was removed by 1:1 TFA/ CH₂Cl₂ for 2 hours. After concentration *in vacuo* the oil was redissolved in CH₂Cl₂ (100 ml) and **2** (4.2 g as the dicyclohexylamine salt of **2**, workup as stated at **2**, 9.4 mmol), BOP (4.2 g, 9.4 mmol) and DiPEA (5.2 ml, 30 mmol) were added. After 2 hours the reaction mixture was concentrated *in vacuo*, redissolved in EtOAc, washed with 1M KHSO₄, 5% NaHCO₃ and brine. After drying of the organic layer over Na₂SO₄ and filtration the product was crystallized from EtOAc/ hexanes and obtained as a white solid (1.8g, 5.1 mmol, 55%).

¹H NMR (CDCl₃): δ = 7.27 (s, 1H, NH) 6.70 (s, 1H, NH), 4.73 (s, 1H, Boc-NH), 4.06 (m, 3H, propargyl-CH₂ + Orn-α-CH), 3.96 (d, 2H, gly-CH₂ *J*=4.7 Hz), 3.15 (m, 2H, Orn-δ-CH₂), 2.26 (s, 1H, alkyne-H), 1.89 (m, 2H, Orn-β-CH₂), 1.62 (m, 2H, Orn-γ-CH₂), 1.44 (s, 9H, Boc-CH₃).

(s, 9H, Boc-CH₃). ¹³C NMR (CDCl₃): δ = 170.5, 168.4, 156.2, 79.32, 79.26, 71.6, 62.8, 42.9, 39.7, 29.11, 29.08, 28.4, 25.9

Triisopropylsilyl-((S)-2-azido-5-((tert-butoxycarbonyl)amino)pentanoyl-glycyl)-propargylamine (4b)

This procedure was analogous to the preparation of 4a, using the following amounts: **3b** (4.0 g, 10.8 mmol), and **2** (4.8 g as the dicyclohexylamine salt of **2**, workup as stated at **2**, 10.8 mmol), BOP (4.8 g, 10.8 mmol) and DiPEA (5.7 ml, 32.4 mmol).

Purification by column chromatography instead of crystallization was performed using 10% acetone in CH_2Cl_2 to obtain **4b** as a colourless oil (4.1 g, 8.1 mmol, 75%)

¹H NMR (CDCl₃): δ = 7.21 (s, 1H, NH), 6.29 (s, 1H, NH), 4.70 (s, 1H, Boc-NH), 4.11 (m, 2H, propargyl-CH₂), 4.03 (m, 1H, Orn-α-CH), 3.93 (d, 2H, glycine-CH₂, *J*=5.3 Hz), 3.15 (m, 2H, Orn-δ-CH₂), 1.89 (m, 2H, Orn-β-CH₂), 1.63 (m, 2H, Orn-γ-CH₂), 1.42 (s, 9H, Boc-CH₃), 1.04 (s, 21H, TIPS)

¹³C NMR (CDCl₃): δ = 170.3, 167.7, 156.2, 102.1, 85.1, 79.4, 63.0, 43.0, 39.5, 30.4, 29.2, 28.4, 26.0, 18.5, 11.1

Tetraacetylated carboxymethyl galactoside-OSu ester (6)

Carboxymethyl tetraacetyl galactoside^{3,4,5} (1.0 g, 2.5 mmol) and Nhydroxysuccinimide (0.3 g, 2.7 mmol) were dissolved in dry CH_2Cl_2 (50 ml) and cooled on ice. DCC (0.6 g, 2.7 mmol) was subsequently added and the reaction mixture was stirred for 16 hours at room temperature. Precipitated DCU was removed by filtration and after concentration *in vacuo* to near dryness, more precipitation occurred. After another filtration step the product was crystallized from $CH_2Cl_2/$ *i*PrOH to yield **6** as white fluffy needles (1.0 g, 2 mmol, 82%)

¹H NMR (CDCl₃): δ = 5.44 (bs, 1H, 4-H), 5.37 (m, 1H, 2-H), 5.20 (m, 1H, 3-H), 4.79 (dt, 1H 1-H, J_1 = J_2 =6.3 Hz,), 4.30-4.10 (m, 3H, 5-H+6-CH₂), 3.00 (m, 2H, 1-CH₂), 2.84 (s, 4H, 2xCH₂-Osu), 2.13 (s,

3H, acetyl-CH₃), 2.08 (s, 3H, acetyl-CH₃), 2.043 (s, 3H, acetyl-CH₃), 2.037 (s, 3H, acetyl-CH₃)

¹³C NMR (CDCl₃): $\delta = 170.5$, 170.0, 169.8, 169.6, 168.7, 165.6, 69.5, 68.6, 67.9, 67.2, 67.0, 60.9, 30.4, 25.5, 20.6

Triisopropylsilyl-((S)-2-azido-5-((peracetyl-1-carboxymethyl galactopyranoside)-amino)pentanoyl-glycyl)-propargylamine (5b)

4b (280 mg, 0.55 mmol) was Boc-deprotected in 1:1 TFA/ CH_2Cl_2 for two hours. After concentration *in vacuo* the oil was redissolved in CH_2Cl_2 (20 ml) and DiPEA (0.26 ml, 1.5 mmol) and **6** (195 mg, 0.5 mmol) were added. The reaction mixture was allowed to stir for 2 hours after which it was concentrated *in vacuo* and redissolved in EtOAc and subsequently washed with 1 M KHSO₄, 5% NaHCO₃ and saturated NaCl. The organic layer was dried with Na₂SO₄ and after evaporation crude **5b** was obtained.

Column chromatography using 4% MeOH in CH₂Cl₂ afforded **5b** as a colourless oil. (327 mg, 0.42 mmol, 84%)

¹³C NMR (CDCl₃): $\delta = 170.6$, 170.2, 170.0, 169.9, 169.7, 169.6, 167.8, 102.2, 84.9, 69.2, 69.0, 67.9, 67.8, 67.0, 62.9, 61.2, 42.7, 38.5, 34.3, 30.4, 29.1, 25.3, 20.7, 18.5, 11.0

((S)-2-azido-5-((peracetyl-1-carboxymethyl galactopyranoside)amino)pentanoyl-glycyl)-propargylamine (5a)

5b (160 mg, 0.2 mmol) was dissolved in anhydrous THF (25 ml). Phenol (96 mg, 1.0 mmol) and TBAF.3H₂O (323 mg, 1.0 mmol) were added and the reaction mixture was stirred for 2h. The reaction mixture was diluted with EtOAc and washed with H₂O. After drying the organic layer with Na₂SO₄ and concentration *in vacuo*, the compound was purified through a small plug of silica using 4% MeOH in CH₂Cl₂ to yield **5a** as a white foam (113 mg, 0.18 mmol, 90%)

¹H NMR (CDCl₃): δ =7.35 (bt, 1H, NH, *J*=~5 Hz), 6.87 (bt, 1H, NH, *J*=~5 Hz), 6.62 (bt, 1H, NH, *J*=~5 Hz), 5.42 (bs, 1H, 4-H glycoside), 5.27 (m, 1H, 2-H glycoside), 5.19 (m, 1H 3-H glycoside), 4.70 (m, 1H, 1-H glycoside), 4.3-4.0 (m, 6H, 5-H, 6-CH₂ glycoside, propargyl-CH₂ Orn-α-CH), 3.97 (d, 2H, glycine-CH₂, *J*=5.1 Hz), 3.31 (m, 2H, Orn-δ-CH₂), 2.7-2.4 (m, 2H, 1-CH₂ glycoside), 2.29 (s, 1H, alkyne-CH), 2.13 (s, 3H, acetyl-CH₃), 2.08 (s, 3H, acetyl-CH₃), 2.06 (s,2x3H, acetyl-CH₃), 1.91 (m, 2H, Orn-β-CH₂), 1.66 (m, 2H, Orn-γ-CH₂)

¹³C NMR (CDCl₃): δ = 170.7, 170.3, 170.01, 169.96, 169.8, 169.7, 168.2, 79.2, 71.8, 69.3, 69.0, 67.9, 67.8, 67.0, 62.8, 61.2, 42.8, 38.5, 34.3, 29.2, 29.1, 25.1, 20.7, 20.6,

Conditions for copper click mediated oligomerization

Azido/alkyne-monomer **5a** (100 mg, 160 μ mol) was dissolved in a DiPEA/DMF solution (400 μ l, 300 mM) in a 1.5 ml plastic reaction tube. A freshly prepared aqueous solution of TCEP (200 mM, 200 μ l), was added to the monomer and shaken for 2 hours after which nitrogen evolution had ceased. Polymerization was then initiated by adding an aqueous copper sulfate solution (240 mM, 100 μ l) followed by a freshly prepared aqueous sodium ascorbate solution (720 mM, 100 μ l), added while vortexing. After 2 h the reaction mixture was diluted with acetonitrile/ water (1:2 v/v, 0.1% TFA added) and preparative HPLC was performed to separate oligomers by size. After lyophilisation the oligomers **7a**, **8a** and **9a** were

obtained as white fluffy solids.

MALDI-TOF:

Trimer 7a (6 mg), calculated *M* for $C_{78}H_{110}N_{16}O_{36}$ 1846.7, found $[M+H]^+$ 1848.4, $[M+Na]^+$ 1870.5, $[M+K]^+$ 1886.7, $[M-acety]+Na]^+$ 1828.3.

 $\begin{array}{l} \textbf{Tetramer 8a} \hspace{0.1cm} (5.5 \hspace{0.1cm} \text{mg}), \hspace{0.1cm} \text{calculated} \hspace{0.1cm} \textit{M} \hspace{0.1cm} \text{for} \hspace{0.1cm} C_{104}H_{146}N_{22}O_{48} \hspace{0.1cm} 2471.0, \\ \textbf{found} \hspace{0.1cm} \left[\textit{M+Na}\right]^{+} \hspace{0.1cm} 2494.4, \hspace{0.1cm} \left[\textit{M+K}\right]^{+} \hspace{0.1cm} 2510.4 \hspace{0.1cm} \left[\textit{M-acetyl+Na}\right]^{+} \hspace{0.1cm} 2452.4. \end{array}$

Pentamer 9a (4 mg), calculated *M* for $C_{130}H_{182}N_{28}O_{60}$ 3095.2, found $[M+Na]^+$ 3118.0, $[M+K]^+$ 3133.9, [M-acetyl+Na]⁺ 3075.9.

Higher oligomers (>7mer, 30 mg), found $[8mer+Na]^+$ 4990.8, $[9mer+Na]^+$ 5615.8, $[10mer+Na]^+$ 6239.2, higher oligomers did not ionize well enough to be distinguishable from the baseline noise.

Synthesis of reference compound OGG-Gal (1) and the C-terminal carboxamide analog 11

Fmoc-Orn(Boc)-OSu (5.0 g, 9.1 mmol) (this N-hydroxysuccinimide ester of the commercially available protected amino acid was synthesized using the methodology described for compound **6** with 88% yield) was dissolved in THF (150 ml). To this solution, a solution of H-Gly-Gly-OH (1.3 g, 10 mmol) and NaHCO₃ (1.68 g, 20 mmol) in water (30 ml) were added. The reaction mixture was stirred for 16 hours, after which the THF was mostly removed *in vacuo* and the mixture was diluted with EtOAc. Washing with 1M KHSO₄ and drying gave the crude Fmoc-Orn(Boc)-Gly-Gly-OH, which was further purified by crystallization from CH₂Cl₂/hexanes to give a white solid (4.6 gram, 8.1 mmol) which was used directly for the next reaction.

Removal of the Boc-group from the ornithine residue (3.0 gram, 5.3 mmol) was performed with 1:1 TFA/CH₂Cl₂ for 2 hours after which the reaction mixture was concentrated in vacuo and coevaporated with toluene to remove residual TFA. The residue was suspended in THF/H₂O (1:1 v/v, 100 ml) and the pH was adjusted to 8.5 with DiPEA. Carbohydrate derivative 6 (2.3 g, 4.8 mmol), dissolved in THF was added and the pH was kept at 8 for 3 hours. The now homogeneous reaction mixture was acidified with 1M KHSO4 and extracted with EtOAc. The combined organic layers were dried on Na₂SO₄, concentrated in vacuo, and the residue was recrystallized from CH₂Cl₂ (with a few drops of MeOH) by addition of Et₂O. Fmoc-Orn(carboxymethyl-Gal)-Gly-Gly-OH was obtained as a white powder (2.8 gram, 3.3 mmol, 61% over the combined three ¹H-NMR was comparable to previously published steps). characterization.5

Solid phase chemistry was performed as previously described on a preloaded Fmoc-Gly-wang resin (to obtain compound 1) or Fmoc-Rink resin (to obtain compound 11) to yield the tetramer,⁵ which after deprotection (see below) was purified by preparative HPLC, using 0.1% TFA in water as buffer A to give retention and subsequently lyophilized to yield compound 1 and 11 as white fluffy solids.

CuAAC coupling of ethyl azidoacetate

Tetramer **8a** (6.5 mg, 2.5 µmol) and ethyl azidoacetate (1 mg, 7.5 µmol, 3 equiv.) were dissolved in THF (400 µl). To this solution copper(II)sulfate pentahydrate (0.2 mg, 0.8 µmol, 0.33 equiv. in 100 µl water) was added followed by sodium ascorbate (1 mg, 5 µmol 2 equiv. in 100 µl water). The reaction mixture was stirred for 6 hours, diluted with EtOAc, and washed with Na₂S₂O₃ solution. The resulting crude glycopeptide was deacetylated (see below) and purified with preparative HPLC using 0.1% TFA in water as buffer A.

Typical Procedure for deacetylation

Acetylated glycopeptide oligomer was dissolved in dry MeOH (500

 μ l/ 5 mg oligomer) and a catalytic amount of fresly prepared sodium methoxide was added. After 3 hours of reaction time water (500 μ l/ 5 mg oligomer) was added to solubilize the formed precipitate and incubated for another 30 minutes. Dowex marathon C ion exchange resin (acid form and washed beforehand with methanol) was added to neutralize the reaction mixture. The mixture was filtered and lyophilized to afford the deacetylated oligomers in 2.5-4 mg amounts and the polymer in ~20 mg. Residual salts could be removed by reversed-phase solid phase extraction, washing with water and eluting the compound with gradual increments of MeCN up to 10% v/v MeCN in water.

ESI-MS after purification:

Deprotected triazole based tetramer (8b): calculated M for $C_{72}H_{114}N_{22}O_{32}$ 1798.80, found $[M+2H]^{2+}$ 900.75

Deprotected triazole based tetramer-acid (10): Calculated *M* for $C_{74}H_{117}N_{25}O_{34}$ 1899.82, found $[M+2H]^{2+}$ 950.65

Deprotected OGG-Gal (1): calculated *M* for $C_{70}H_{117}N_{17}O_{38}$ 1803.8, found $[M+2H]^{2+}$ 902.70

Deprotected carboxamide OGG-Gal (11): calculated M for $C_{68}H_{115}N_{17}O_{36}$ 1745.77, found $[M+2H]^{2+}$ 873.70

CD spectroscopy

CD spectra were recorded on a JASCO J-815 spectrometer using a 1 cm cuvet in a Peltier type cell holder operating at 4 °C. A 260-190 nm window was scanned at 50 nm/min with a data pitch of 0.2 nm and an integration time of 1 second. 10 accumulations of these measurements were recorded for each spectrum. The AFGP concentration used was 50 μ M in milli-Q water (freshly made) and water blanks were subtracted. The concentrations used probably correspond to non-aggregated single molecules in solution as was measured for AFGP-8.⁶ SELCON-3 analysis, included in the *CDPro* package and used as described using datasets IBasis 5 (SP37A) and IBasis 10 (SMP56), which contain 37 soluble and 43 soluble+13 membrane proteins respectively, was performed.^{7,8} The CONTINLL and CDSSTR tools yielded less reliable results in terms of solutions.

IBASIS 5	A-helix	B-sht	Turn	PPII	Unrd.
OGG-Gal carboxylic acid 1	0.000	0.335	0.099	0.123	0.444
OGG-Gal carboxamide 11	0.088	0.258	0.046	0.058	0.546
Triazole alkyne 8b	0.087	0.258	0.046	0.058	0.549
Triazole acid 10	0.086	0.258	0.046	0.058	0.549

IBASIS 10	H(r)	H(d)	S(r)	S(d)	Turn	Unrd.
1	0.000	0.029	0.290	0.195	0.227	0.252
11	0.006	0.087	0.295	0.160	0.107	0.337
8b	0.006	0.085	0.297	0.161	0.108	0.338
10	0.006	0.085	0.301	0.162	0.109	0.340

Thermal Hysteresis (TH) assay

Nanoliter osmometry was performed using a Clifton nanoliter osmometer (Clifton Technical Physics, Hartford, NY).⁹ All measurements were performed in a phosphate buffered saline (PBS) solution. Ice crystal morphology was observed through a Leitz compound microscope equipped with an Olympus $20\times$ (infinity-corrected) objective, a Leitz Periplan $32\times$ photo eyepiece, and a Hitachi KPM2U CCD camera connected to a Toshiba MV13K1 TV/VCR system. Still images were captured directly using a Nikon CoolPix digital camera.

Ice Recrystallization Inhibition (IRI) assay

Sample analysis for IRI activity was performed using the "splat cooling" method as previously described¹⁰ In this method, the analyte was dissolved in a phosphate buffered saline (PBS) solution and a 10 μ L droplet of this solution was dropped from a micropipette through a two meter high plastic tube (10 cm in diameter) onto a block of polished aluminum precooled to approximately -80 °C. The droplet froze instantly on the polished aluminum block and was approximately 1 cm in diameter and 20 μ m thick. This wafer was then carefully removed from the surface of the block and transferred to a cryostage held at -6.4 °C for annealing. After a period of 30 min, the wafer was photographed between crossed polarizing filters using a digital camera (Nikon CoolPix 5000) fitted to the microscope. A total of three images were taken from each wafer. During flash freezing, ice crystals spontaneously nucleated from the supercooled solution. These initial crystals were relatively homogeneous in size and quite small. During the annealing cycle, recrystallization occurred, resulting in a dramatic increase in ice crystal size. A quantitative measure of the difference in recrystallization inhibition of two compounds is the difference in the ice crystal size distribution. Image analysis of the ice wafers was performed using a novel domain recognition software (DRS) program.¹¹ This processing employed the Microsoft Windows Graphical User Interface to allow a user to visually demarcate and store the vertices of ice domains in a digital micrograph. The data was then used to calculate the domain areas. All data was plotted and analyzed using Microsoft Excel. The mean grain (or ice crystal) size (MGS) of the sample was compared to the MGS of the control PBS solution for that same day of testing. IRI activity is reported as the percentage of the MGS (% MGS) relative to the PBS control, and the % MGS for each sample was plotted along with its standard error of the mean. Small percentages represent a small MGS, which is indicative of more potent IRI activity.

- 1. E. D. Goddard-Borger and R. V Stick, *Org. Lett.*, 2007, **9**, 3797–3800.
- 2. I. E. Valverde, A. F. Delmas, and V. Aucagne, *Tetrahedron*, 2009, **65**, 7597–7602.
- J. R. Kramer and T. J. Deming, J. Am. Chem. Soc., 2010, 132, 15068–15071.
- 4. A. Giannis and K. Sandhoff, *Tetrahedron Lett.*, 1985, **26**, 1479–1482.
- R. N. Ben, A. A. Eniade, and L. Hauer, *Org. Lett.*, 1999, 1, 1759–1762.
- 6. V. R. Bouvet, G. R. Lorello, and R. N. Ben, *Biomacromolecules*, 2006, 7, 565–571.
- R. Y. Tam, C. N. Rowley, I. Petrov, T. Zhang, N. A. Afagh, T. K. Woo, and R. N. Ben, *J. Am. Chem. Soc.*, 2009, 131, 15745–15753.
- N. Sreerama, S. Y. Venyaminov, and R. W. Woody, *Anal. Biochem.*, 2000, **287**, 243–251.
- A. Chakrabartty and C. L. Hew, *Eur. J. Biochem.*, 1991, 202, 1057–1063.

- 10. C. A. Knight, J. Hallett, and A. L. DeVries, *Cryobiology*, 1988, **25**, 55–60.
- J. Jackman, M. Noestheden, D. Moffat, J. P. Pezacki, S. Findlay, and R. N. Ben, *Biochem. Biophys. Res. Commun.*, 2007, **354**, 340–344.

4 | J. Name., 2012, **00**, 1-3